

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory et al.

Examiner: Dr. K. C. Carlson

Serial No: 08/087,132

Art Unit: 1812

Filed: July 2, 1993

Docket: IG 4-9.2(FWC)

Title: New Diagnostic and Treatment Methods Involving the
Cystic Fibrosis Transmembrane RegulatorRECEPTIONIST
RECEIVED

JAN 18 1996

The Honorable Commissioner of Patent and Trademarks
Washington, DC 20231

GROUP 1800

Dear Sir:

Transmitted herewith is an AMENDMENT in the above identified application.


1. The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUS PAID FOR	NUMBER OF EXTRA	RATE LARGE ENTITY	FEE
TOTAL	37	MINUS	133	= 0	x 22	\$ 0
INDEP	6	MINUS	13	= 0	x 76	\$ 0
MULTIPLE DEPENDENT CLAIMS					x 240	0
TOTAL ADDITIONAL FEES						\$ 0

NO NEW MULTIPLE DEPENDENT CLAIMS ARE BEING ADDED

TOTAL \$ 0

2. The Commissioner is hereby authorized and requested to charge \$ 0 for the presentation of extra claims under 37 C.F.R. 1.16 and all patent processing fees under 37 C.F.R. 1.17, along with any additional fees under 37 C.F.R. 1.16 and 1.17, which may be required, or credit any overpayment, associated with this communication to Deposit Account No. 07-1074. A duplicate of this document is enclosed for this purpose.
3. Since the number of independent claims and the number of total claims that are now pending herein are substantially less than the numbers thereof that have been previously paid for, no fee is due in connection with this supplementary submission. However, the Patent Office is authorized to charge any fee that it determines is necessary in order to secure the filing of this Supplementary Reply and all enclosures.

Respectfully submitted,
GENZYME CORPORATION

 Elizabeth Lassen, Esquire
 Reg. No. 31,845
 Attorney for Applicants

Dated: January 17, 1996